117973-14-5

Basic information

• Product Name: Magnesium, bromo[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-
• CAS NO: 117973-14-5
• Molecular Formula: C12H19BrMgOSi
• Molecular Weight: 311.577
• Mol File: 117973-14-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Magnesium, bromo[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Magnesium, bromo[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-(117973-14-5)
• EPA Substance Registry System: Magnesium, bromo[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-(117973-14-5)

Safety Data

• Hazardous Substances Data: 117973-14-5(Hazardous Substances Data)

Upstream product

• 65423-56-5 1-bromo-3-[(tert-butyldimethylsilyl)oxy]benzene 
• 591-20-8 3-Bromophenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 122483-58-3 1-[3-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-3-(3,4,5-trimethoxy-phenyl)-propan-1-ol 
• 878021-25-1 2-[3-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2,5-dimethyl-3,4-dihydro-2H-pyrrole 1-oxide 
• 155765-75-6 4-[(3-{[tert-butyl(dimethyl)silyl]oxy}phenyl)(hydroxy)methyl]-N,N-diethylbenzamide 
• 216532-22-8 4-{(R)-((2S,5R)-4-allyl-2,5-dimethyl-piperazin-1-yl)-[3-(tert-butyl-dimethylsilanyloxy)-phenyl]-methyl}-benzonitrile 
• 199938-29-9 1-(tert-butyloxycarbonyl)-4-[3-{3-(tert-butyldimethylsilyloxy)phenyl}-3-hydroxy-3-phenylpropyl]homopiperazine 
• 155836-50-3 4-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide 
• 419544-78-8 4-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-trifluoromethylsulfonyloxybenzyl)-N,N-diethylbenzamide 
• 214606-86-7 (+)-4-[(αR)-α-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-3-hydroxybenzyl]-N,N-diethylbenzamide 
• 419544-49-3 (-)-3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(thien-3-yl)methyl)phenol 

Relevant articles and documents

AN OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION

The present invention relates to a method of treating drug addiction and reducing dependence or tolerance on a dependence-inducing opiate drug, wherein the method comprises administering to a subject a compound having the structure of formula (I): having

METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY

Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and option

Method of treating depression with delta receptor agonist compounds

Compositions and methods for treatment of depression or other affective mood disorders or pathological mental and/or emotional states, by administration to a subject suffering or susceptible to same, of therapeutically effective delta receptor agonist com